News

ivWatch Names Kathy Cox as Chief Financial Officer

ivWatch, LLC, inventor of the first and only continuous IV infiltration detection technology, appointments Kathy Cox to Chief Financial Officer. With over 23 years of experience, including 15 years in the medical device manufacturing and healthcare markets, Cox will strengthen the ivWatch leadership team and will provide expertise in driving business growth and operational efficiencies. She will lead the Accounting and Finance functions and report directly to President and Chief Executive Officer Gary Warren.

“Kathy is an exciting addition to our leadership team,” said Gary Warren, President and CEO, ivWatch. “Her strength as a leader at several medical device manufacturers and healthcare companies both privately owned and those held by global publicly-traded parent companies will be invaluable as we continue to grow our company, execute against our long-term strategies, and work to deliver breakthrough technologies to hospitals around the globe.”

“I am thrilled to join ivWatch and work alongside a team of inventors that will continue to improve patient safety and care through relentless innovation,” said Kathy Cox. “The company has a proven track record of putting people first to advance IV therapy and I am excited to bring my knowledge and experience throughout my career to help drive the trajectory of ivWatch and fulfill its mission.”

Prior to joining ivWatch, Cox held a series of executive positions for 12 years within Solesis, an operating division of Michelin and Fenner PLC, including Director/General Manager. She also held the role of Finance Director at Charter Medical and at Xeridiem Medical Devices. Over the course of her career, Cox has developed technical expertise in all aspects of corporate finance, financial planning, and accounting. Her Director/General Manager experience provides her with a strategic business view and commercial mindset that assists in communication of financial data across functional areas of a corporation. She specializes in leading transformative change in teams, processes, and systems to support revenue growth.

Cox, an active CPA since 2000, graduated from Florida State University in Tallahassee, Florida with a B.S. in Accounting.

Recent News

06/11/2026

Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing

Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”) today announced that it has acquired Azora Therapeutics, Inc. (“Azora”), a biopharmaceutical company developing treatments for serious inflammatory diseases. The acquisition brings Azora’s lead asset AT177, a proprietary colon‑targeted aryl hydrocarbon receptor (AhR) agonist designed to enable localized activation with limited systemic exposure, into Adial’s pipeline.

06/11/2026

Luna Labs Launches 3 Waves Venture Spinout to Commercialize Advanced Vestibular Stimulation Technology

Luna Labs today announced the launch of 3 Waves, Inc. (“3Waves”), a dual-use spinout company that was established to commercialize advanced virtual and mixed reality technologies for defense, commercial simulation, and medical applications. As part of the spinout, 3Waves and Mayo Clinic executed an exclusive license to support the development of next-generation vestibular stimulation systems

06/02/2026

TearSolutions Receives FDA Orphan Drug and Fast Track Designations for Lacripep® in Neurotrophic Keratitis and Initiates Phase 2 Clinical Trial with First Patients Dosed

TearSolutions, Inc. (“TearSolutions”), a clinical-stage biotechnology company developing novel ophthalmic therapeutics, today announced receiving Food and Drug Administration (FDA) Orphan Drug (ODD) and Fast Track Designations for Lacripep in Neurotrophic Keratitis (NK) and initiating a Phase 2 clinical trial with first patients dosed. The FDA’s ODD provides incentives, including tax credits for clinical testing and